Chest Medicine
[Preprint] Multi-organ impairment in low-risk individuals with long COVID
18 Oct, 2020 | 23:18h | UTCMulti-organ impairment in low-risk individuals with long COVID – medRxiv
Related study (preprint): Persistent symptoms after Covid-19: qualitative study of 114 long Covid patients and draft quality criteria for services – medRxiv
Commentary on Twitter
"In a young, low-risk population with ongoing symptoms, almost 70% of individuals have impairment in 1 or more organs 4 months after initial symptoms of #SARSCoV2 infection" #LongCovid https://t.co/gPnDtacI1J by @amibanerjee1 and colleagues
via @ahandvanish<-🙏 pic.twitter.com/7mKEsQgq5l— Eric Topol (@EricTopol) October 17, 2020
Improving prone positioning for severe ARDS during the COVID-19 pandemic: An implementation mapping approach
18 Oct, 2020 | 23:17h | UTC
Commentary on Twitter
Improving Prone Positioning for Severe ARDS during the COVID-19 Pandemic: An Implementation Mapping Approach
✅ Just Accepted
🔗 https://t.co/V8K3MUdSWU pic.twitter.com/wPJCp2mKaE— Annals of the ATS (@AnnalsATS) October 13, 2020
New studies show reduced prevalence and severity of SARS-CoV-2 infection in ABO blood group O
18 Oct, 2020 | 23:16h | UTCStudy 1: Reduced prevalence of SARS-CoV-2 infection in ABO blood group O – Blood Advances
Commentaries: People with blood type O may have lower risk of Covid-19 infection and severe illness, two new studies suggest – CNN AND Studies offer new evidence for possible link between blood type and COVID-19 susceptibility – American Society of Hematology
Answering key questions about COVID-19 vaccines
18 Oct, 2020 | 23:10h | UTCAnswering Key Questions About COVID-19 Vaccines – JAMA
Commentary on Twitter
Many individuals are hesitant about receiving #COVID19 vaccines. It is critical that clinicians stay well informed about emerging data so that they can help patients make sound decisions https://t.co/1QDwOKuDqc @JesseGoodmanMD @ImmunizeOrg @pharmacists
— JAMA (@JAMA_current) October 16, 2020
NIHR dynamic review of the evidence around ongoing Covid19 symptoms (often called Long Covid)
18 Oct, 2020 | 23:14h | UTCA dynamic review of the evidence around ongoing Covid19 symptoms (often called Long Covid) – National Institute for Health Research
News Release: Living with COVID: NIHR publishes dynamic themed review into ‘ongoing COVID’
Commentaries: Coronavirus: ‘Long Covid could be four different syndromes’ – BBC AND Long covid could be four different syndromes, review suggests – The BMJ AND ‘Long COVID’ may affect multiple parts of body and mind, doctors say – Reuters
Acute Respiratory Distress Syndrome: Contemporary management and novel approaches during COVID-19
18 Oct, 2020 | 23:11h | UTCSource: Grupo UTI Clínica HCFMUSP
Commentary on Twitter
Review article in @_Anesthesiology showing a summary of 25 yr of ARDS intervention trials and contemporary management and novel approaches during COVID-19 ✅#ICU #CriticalCare #COVID__19 #ARDS https://t.co/MjLGgoTGy6 pic.twitter.com/wkVoOikhKQ
— Alice Blet, MD, PhD 🩺🔬 (@BletAlice) October 9, 2020
Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
18 Oct, 2020 | 23:07h | UTC
Commentary on Twitter
The cytokine storm of severe #COVID19 and how it differs from ARDS, sepsis, and CAR-T cytokine release syndrome. Best review to date on this ★
Today @LancetRespirMed https://t.co/BOUjvIOWLi @danleisman @Poietic_Justice @IcahnMountSinai @CDMD62
🙏 for pulling all this together pic.twitter.com/qZCPbrxvYU— Eric Topol (@EricTopol) October 16, 2020
[Preprint] WHO SOLIDARITY trial results published; Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon do not improve outcomes in Covid-19
16 Oct, 2020 | 09:42h | UTCRepurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results – medRxiv
Commentary: Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments – Science
Commentaries on Twitter
Results of the @WHO SOLIDARITY trial:
4 drugs tested in 11,266 patients with COVID in 405 hospitals in 30 countries:
– hydroxychloroquine
– lopinavir
– remdesevir
– interferonNo clear benefit of any of them on survival. https://t.co/ohtTAFaSnc pic.twitter.com/2fO9E8zs8h
— Martin Landray (@MartinLandray) October 16, 2020
This is blockbuster from @WHO: 'Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens have little or no effect on hospitalized COVID-19, as indicated by mortality, initiation of ventilation and duration of hospital stay. @medrxivpreprint https://t.co/aNGLzLL5uW pic.twitter.com/daOAMVW62u
— Harlan Krumholz (@hmkyale) October 15, 2020
Scientific consensus on the COVID-19 pandemic: we need to act now
16 Oct, 2020 | 09:41h | UTCScientific consensus on the COVID-19 pandemic: we need to act now – The Lancet
Viewpoint: Sensible medicine—balancing intervention and inaction during the COVID-19 pandemic
16 Oct, 2020 | 09:38h | UTCSensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic – JAMA
Author interview: Sensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic
Commentary on Twitter
https://twitter.com/seymoc/status/1316765788523511809
Cochrane living systematic review: Not enough evidence to recommend convalescent plasma for people with COVID‐19
16 Oct, 2020 | 09:34h | UTC
Commentary on Twitter
Just updated: @CochraneCollab living review investigates the use of convalescent plasma to treat people with COVID-19: https://t.co/Or5qmxki8H “We remain very uncertain about the effectiveness & safety of using convalescent plasma for people with #COVID19".
— The Cochrane Library (@CochraneLibrary) October 13, 2020
Randomized trial: Effect of sustained smoking cessation counseling and free medication vs. shorter-term counseling and medication advice on smoking abstinence
16 Oct, 2020 | 09:23h | UTCCommentary: Long-term, frequent phone counseling helps cancer patients who smoke quit – eCancer
IDSA Position Statement: “Herd immunity” is not an answer to a pandemic
15 Oct, 2020 | 09:31h | UTC“Herd Immunity” is Not an Answer to a Pandemic – Infectious Diseases Society of America
Commentary on Twitter
https://t.co/k15V8bMjiK via @IDSAInfo Excellent statement from @IDSAInfo & @HIVMA Presidents of why "herd immunity" is not an answer to a pandemic. These is the professional association representing > 12K specialists in infectious diseases so these are the real experts!
— Carlos del Rio (@CarlosdelRio7) October 14, 2020
Updated Cochrane Review shows electronic cigarettes can help people quit smoking
16 Oct, 2020 | 09:21h | UTCUpdated Cochrane Review shows electronic cigarettes can help people quit smoking – Cochrane Library
Original study: Electronic cigarettes for smoking cessation – Cochrane Library
Commentary on Twitter
https://twitter.com/CochraneUK/status/1316475634445672448
Review: The duration of infectiousness of individuals infected with SARS-CoV-2
15 Oct, 2020 | 09:26h | UTCThe duration of infectiousness of individuals infected with SARS-CoV-2 – Journal of Infection
Commentary on Twitter
🔥NEW Review🔥#COVID19 pts with mild-to-moderate illness are highly unlikely to be infectious beyond 10 ds from symptom onset , However, limited studies found that Immunocompromised and severe-to-critical patients may be infectious for >10 days https://t.co/hogXvFpPEb pic.twitter.com/fBm5Se4RBf
— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) October 13, 2020
Coronavirus vaccine: What we know so far – a comprehensive guide by academic experts
15 Oct, 2020 | 09:17h | UTC
WHO Global tuberculosis report 2020
15 Oct, 2020 | 09:35h | UTCGlobal tuberculosis report 2020 – World Health Organization
News release: WHO: Global TB progress at risk – World Health Organization
Executive summary: Global tuberculosis report 2020
Commentary: WHO warns of COVID impact on TB services – CIDRAP
Commentary on Twitter
The 🌏🌍🌏 has made steady progress in tackling tuberculosis (TB), with a 1⃣4⃣% drop in deaths between 2015 and 2019.
🚨 #COVID19 will lead to setbacks if no action is taken urgently, according to 🆕 WHO report 👉https://t.co/5BvbGjaudU pic.twitter.com/A4edYfyOBH
— World Health Organization (WHO) (@WHO) October 14, 2020
Cluster randomized trial: Incentive programs for smoking cessation
15 Oct, 2020 | 09:09h | UTC
Commentary on Twitter
NEW paper @bmj_latest: #RCT of multiple incentive types for #smoking cessation in worksites in Thailand (SMILE trial). Large individual bonus most effective. https://t.co/CNdvhOo7Sb
With @WilliamHDow @c_lowenstein @UCBerkeleySPH and Aree Jampklay, Nucharee Srivirojana @MahidolU pic.twitter.com/q9B61wyzrf
— Justin White (@justinswhite) October 14, 2020
Genomic evidence for reinfection with SARS-CoV-2: A case study
14 Oct, 2020 | 09:39h | UTCGenomic evidence for reinfection with SARS-CoV-2: a case study – The Lancet Infectious Diseases
Commentaries: First Case Of COVID-19 Reinfection In The US Confirmed; Exposure to Virus May Not Guarantee Protective Immunity, Says New Lancet Study – Health Policy Watch AND What reinfections mean for COVID-19 – The Lancet Infectious Diseases AND You can get reinfected with Covid-19 but still have immunity. Let’s explain. – Vox AND A 25-Year-Old Nevada Man Got COVID-19 Twice. Here’s What We Know—and Don’t Know—About Reinfection – TIME
Related: Dutch woman dies after catching Covid-19 twice, the first reported reinfection death – CNN
Updated NIH COVID-19 Treatment Guidelines
14 Oct, 2020 | 09:41h | UTCCoronavirus Disease 2019 (COVID-19) Treatment Guidelines – National Institutes of Health
See also: What’s New in the Guidelines
Johnson & Johnson Covid-19 vaccine study paused due to unexplained illness in participant
14 Oct, 2020 | 09:31h | UTCJohnson & Johnson Covid-19 vaccine study paused due to unexplained illness in participant – STAT
News Release: Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials
Commentaries: Johnson & Johnson ‘Pauses’ COVID-19 Vaccine Trial Due To Unexplained Illness In Participant; Eli Lilly Reportedly Suspending Trial Of Antibody Treatment – Health Policy Watch AND Johnson & Johnson pauses Covid-19 vaccine trial after ‘unexplained illness’ – CNN
Non-respiratory presentations of COVID-19, a clinical review
14 Oct, 2020 | 09:33h | UTC
Monoclonal antibody trial halted for safety concern
14 Oct, 2020 | 09:30h | UTCMonoclonal Antibody Trial Halted for Safety Concern – Brief19
Opinion piece by Dr. John P.A. Ioannidis: Global perspective of COVID‐19 epidemiology for a full‐cycle pandemic
13 Oct, 2020 | 01:15h | UTC
Pursuing COVID ‘herd immunity’ without a vaccine could be dangerous & unethical, WHO warns
13 Oct, 2020 | 01:16h | UTC